12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Riociguat regulatory update

Bayer said FDA accepted and granted Priority Review to an NDA for riociguat to treat pulmonary arterial hypertension (PAH) and inoperable chronic...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >